Immunotherapy before surgery for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two immunotherapy drugs (pembrolizumab and N-803) with or without special immune cells (PD-L1 t-haNK cells) before surgery for head and neck cancer. The goal is to see if this treatment can shrink the cancer or improve the outcome after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with squamous cell carcinoma of the head or neck that has not been treated yet and is considered intermediate or high risk.
- Your cancer tests negative for p16 (a marker related to HPV), especially if it started in the oropharynx (back of the throat).
- You are 18 years or older and your overall health is fairly good (ECOG 0 or 1).
- You are scheduled to have surgery to remove the cancer.
- Your blood counts, liver, kidney, and clotting functions are within acceptable ranges as checked by tests.
- You are willing to have a biopsy before and after the treatment, and if you are of childbearing potential, you agree to use effective birth control during and for 4 months after the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose radiation and an immunotherapy drug (similar to Keytruda) given before surgery for advanced head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests giving a combination of two drugs (an immunotherapy drug called a PD-1 inhibitor and a targeted therapy called cetuximab) before surgery to shrink head and neck cancers. The goal is to see if this approach lowers the chance of the cancer coming back after surgery.
This trial tests a combination of an immunotherapy drug (tirelizumab) with two chemotherapy drugs before surgery for head and neck cancer that has spread to lymph nodes. The goal is to shrink the tumor and improve treatment outcomes.
This trial tests a new immunotherapy drug (adelbelimab) combined with chemotherapy given before surgery, for people with head and neck cancer. The goal is to see if this combination can shrink the tumor and improve the chances of successful surgery.
This trial studies whether pembrolizumab, given before surgery, can improve outcomes for certain people with stage III–IVA head and neck squamous cell cancer. It’s typically added alongside low-dose PFAS as part of treatment leading up to standard surgery and afterward medicines/radiation.
This study tests a drug called pabliximab (an immunotherapy) given before surgery to shrink head and neck tumors. It aims to make surgery more effective and may improve outcomes for people with this cancer.
Hear when a new Stage II Squamous Cell Carcinoma of the Head and Neck trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.